Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 10/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.64 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.64 |
| ▸ | NPC1 | O15118 | 1/20 | 0.64 |
| ▸ | GMNN | O75496 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
| ▸ | TP53 | P04637 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 1/20 | 0.64 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.64 |
| ▸ | HPGD | P15428 | 1/20 | 0.64 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.64 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.64 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.64 |
| ▸ | RAB9A | P51151 | 1/20 | 0.64 |
| ▸ | BLM | P54132 | 1/20 | 0.64 |
| ▸ | GFER | P55789 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3070629 | 0.88 | PDE5A (0.70) | PDE5ACYP1A2CYP2D6CYP3A4KDM4E | |
| SCHEMBL5370817 | 0.85 | PDE5A (0.65) | PDE5ACYP1A2CYP2D6CYP3A4KDM4E | |
| SCHEMBL3073972 | 0.85 | PDE5A (0.71) | PDE5ACYP1A2CYP2D6CYP3A4KDM4E | |
| SCHEMBL10252544 | 0.81 | PDE5A (0.77) | PDE5ACYP1A2CYP2D6CYP3A4KDM4E | |
| SCHEMBL5564260 | 0.80 | PDE5A (1.00) | PDE5ACYP1A2CYP2D6CYP3A4KDM4E | |
| SCHEMBL3077928 | 0.79 | PDE5A (0.70) | PDE5ACYP1A2CYP2D6CYP3A4KDM4E | |
| SCHEMBL29352550 | 0.78 | PDE5A (1.00) | PDE5ACYP1A2CYP2D6CYP3A4KDM4E | |
| SCHEMBL1900992 | 0.78 | PDE5A (0.70) | PDE5ACYP1A2CYP2D6CYP3A4KDM4E | |
| SCHEMBL187837 | 0.78 | PDE5A (1.00) | PDE5ACYP1A2CYP2D6CYP3A4KDM4E | |
| SCHEMBL5362975 | 0.78 | PDE5A (0.68) | PDE5ACYP1A2CYP2D6CYP3A4KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1418176-B1 | Pyrazole derivates, their preparation and their use in drugs | SANOFI AVENTIS DEUTSCHLAND (DE) | 2010-04-28 | — | — | EP | disclosed |
| US-7300950-B2 | Pyrazole derivatives, their preparation and their use in pharmaceuticals | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2007-11-27 | — | — | US | disclosed |
| US-20050176799-A1 | Pyrazole derivatives, their preparation and their use in pharmaceuticals | AVENTIS PHARMA DEUTSCHLAND GMBH. | 2005-08-11 | — | — | US | disclosed |
| US-6897232-B2 | Pyrazole derivatives, their preparation and their use in pharmaceuticals | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-05-24 | — | — | US | disclosed |
| EP-1418176-A1 | Pyrazole derivates, their preparation and their use in drugs | Aventis Pharma Deutschland GmbH (DE) | 2004-05-12 | — | — | EP | disclosed |
| US-20030105336-A1 | Pyrazole derivatives, their preparation and their use in pharmaceuticals | AVENTIS PHARMA DEUTSCHLAND GMBH | 2003-06-05 | — | — | US | disclosed |
| US-6162819-A | Pyrazole derivatives, their preparation and their use in pharmaceuticals | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2000-12-19 | — | — | US | disclosed |
| CN-1214339-A | Pyrazole derivatives, their preparation and their use in pharmaceuticals | HOECHST MARION ROUSSEL DE GMBH (DE) | 1999-04-21 | — | — | CN | disclosed |
| EP-0908456-A1 | Pyrazole derivatives, their preparation and their use in drugs | Hoechst Marion Roussel Deutschland GmbH (DE) | 1999-04-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176799-A1 | Pyrazole derivatives, their preparation and their use in pharmaceuticals | PDE3A, PDE3B, PDE5A | PDE5A 3/4885CYP1A2 85/4885CYP2D6 506/4885 |
| US-20030105336-A1 | Pyrazole derivatives, their preparation and their use in pharmaceuticals | PDE3B, PDE3A, PDE5A | PDE5A 3/4885CYP1A2 106/4885CYP2D6 524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.